根据年龄分析奥拉帕利在BRCA1/2突变复发性铂敏感卵巢癌患者中的疗效与安全性:III期SOLO2/ENGOT-Ov21研究分析
该研究基于SOLO2试验的295例BRCA1/2突变复发性铂敏感卵巢癌患者,以65岁为界分析奥拉帕利与安慰剂的疗效、耐受性及生活质量。结果显示两年龄组无进展生存获益无显著差异,但老年组总生存获益未观察到,且因毒性停药率和AML/MDS发生率更高,作者建议对老年患者密切监测。
要点
- ≥65岁与<65岁患者无进展生存获益无显著差异(交互作用P=0.33)。
- 年轻患者中奥拉帕利组的总生存获益在老年患者中未观察到。
- 老年患者因毒性停药率和AML/MDS发生率更高,需密切监测。
核心结论
- 在BRCA1/2突变复发性铂敏感卵巢癌患者中,奥拉帕利维持治疗无论年龄均显示出显著疗效。
- 鉴于老年患者停药率更高、AML/MDS频率更高且总生存无明确获益,作者建议对老年患者保持谨慎、密切监测和随访。
研究设计与样本
- SOLO2试验(III期)中随机分配至奥拉帕利或安慰剂的295例患者,按65岁年龄切点分组分析。
主要发现
- ≥65岁患者62例(21.0%),<65岁患者233例(78.9%),基线特征相似。
- 无进展生存获益:≥65岁组(N=40)HR 0.43(95%CI 0.24-0.81),<65岁组(N=155)HR 0.31(95%CI 0.22-0.43),交互作用P=0.33。
- 年轻患者中奥拉帕利组的总生存获益在老年患者中未观察到。
- 两组安全性和生活质量评分相当,但老年亚组因毒性停药率更高、AML/MDS频率更高。
- TWiST分析显示两年龄组奥拉帕利治疗期间良好生活质量持续时间有临床意义(≥65岁:13.5个月 vs <65岁:18.4个月,P=0.05)。
临床怎么用
- 作者建议对老年患者使用奥拉帕利时保持谨慎、密切监测和随访。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Olaparib has significantly improved outcome and patient-centered endpoints in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer (PSOC). Specific information on efficacy and safety of olaparib for older patients appears of special interest. METHODS: 295 patients from the SOLO2 trial randomly assigned to olaparib or placebo were categorized according to age-cutoff at 65 years. Efficacy, tolerability, and quality of life (QoL) of olaparib relative to placebo within in each age group was analyzed. RESULTS: Baseline characteristics were similar in patients ≥65 years (N = 62;21.0%) compared to patients <65 years (N = 233;78.9%). No significant difference in the magnitude of progression-free survival (PFS) benefit from olaparib for older patients (N = 40, hazard ratio [HR]≥65 0.43, 95%-confidence interval [CI] 0.24-0.81) as compared with younger patients (N = 155, HR<65 0.31 (95%-CI 0.22-0.43) was seen (interaction P = 0.33). The overall survival (OS)benefit seen in younger patients in the olaparib arm was not observed in older patients. Older and younger patients had comparable safety profiles and QoL scores although higher discontinuation rates for toxicity, and higher frequency of AML/MDS were noted in the older subset. TWiST analysis revealed clinically meaningful duration of good QoL on olaparib for both age groups (≥65: 13.5 vs <65: 18.4 months, P = 0.05). CONCLUSIONS: Results of this large phase III cohort of BRCA1/2-mutated PSOC patients treated with olaparib underline impressive efficacy of olaparib maintenance irrespective of age. Although toxicity and tolerability did not raise significant concerns, some caution, close monitoring, and follow-up needs to be exercised for older patients given higher discontinuation rates, frequency of AML/MDS, and no clear effects on OS.
引用
- Trillsch F, Mahner S, Ataseven B, et al. Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 study. Gynecol Oncol. 2022. PMID: 35115180. doi:10.1016/j.ygyno.2022.01.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。